16.05.2023 - 18.05.2023Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
9:00 am - 4:30 pm
Temas de la conferencia Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.